Perspective Therapeutics has shared interim results from its ongoing Phase I/IIa clinical trial of [212Pb]VMT-α-NET at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. 

The Phase I/IIa clinical trial is a multi-centre open-label dose escalation and dose expansion study of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumours (NETs) who have not received prior radiopharmaceutical therapy (RPT) and whose tumours have shown radiological evidence of disease progression in the 12 months prior to enrolment. 

As of the data cut-off date, no dose limiting toxicities (DLTs), no discontinuations due to adverse events, no Grade 4 or 5 treatment emergent adverse events (TEAEs), and no deaths had been reported since the start of the study.  

Interim trial results

Seven out of nine patients in Cohorts 1 and 2 continued to experience disease control and remained in the study.  

One patient experienced stable disease for 48 weeks after their first dose prior to experiencing progressive disease.  

One patient was previously reported to have progressive disease after one dose under RECIST v1.1, by unambiguous progression of non-target lesions. 

The first patient who experienced a confirmed objective response remained in response for over 10 months and in study. 

Two patients experienced initial responses after the end of their treatment periods, which have since been confirmed in subsequent scans. They remained in response and in study. 

A fourth patient was observed to experience an initial (unconfirmed) response in the seventh scan at 48 weeks after their first dose, which was the third scan conducted after the end of their treatment period. 

“[212Pb]VMT-α-NET is emerging as an exciting potential treatment option for patients with progressive NETs, with continued durability of anti-tumour activity at the dose level used in Cohort 2 and a favourable tolerability profile seen so far,” said Vikas Prasad, Associate Professor of Radiology, Mallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University School of Medicine.

Diana Spencer, Senior Digital Content Editor, DDW